Trial
NCT04482712
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
The Claude D. Pepper Older Americans Independence Centers
Condition
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Intervention
Rapamycin
Why stopped
The study was never submitted to IRB or approved, due to feasibility issues
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-01